Lasium

Rivastigmine, the active ingredient in Lasium, is an acetylcholinesterase inhibitor presented as an oral formulation for oral use. It is indicated for mild to moderate dementia associated with Alzheimer’s disease and Parkinson’s disease. GNH USA supplies Lasium as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Rivastigmine acts on the cholinergic pathway to improve cognition in several dementia syndromes. - Alzheimer’s disease dementia: improves cognitive function and daily activities in mild to moderate stages. - Parkinson’s disease dementia: helps maintain cognition and functional abilities. - Mild to moderate dementia of other etiologies: may provide symptomatic benefit.

Rivastigmine may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional, often transient. - Diarrhea: loose stools that may affect hydration. - Loss of appetite: reduced food intake. - Weight loss: gradual decrease in body weight. - Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects: - Severe vomiting: may lead to dehydration. - Gastrointestinal bleeding: rare but potentially life‑threatening. - Bradycardia: markedly slow heart rate. - Syncope: fainting episodes. - Severe skin reactions: such as rash or Stevens‑Johnson syndrome. - Elevated liver enzymes: indicating possible hepatic involvement.

Before initiating Lasium, clinicians should consider several safety measures. - Dose titration: start low and increase gradually to improve tolerance. - Gastrointestinal monitoring: watch for persistent nausea or vomiting. - Cardiovascular assessment: evaluate heart rate and blood pressure regularly. - Renal/hepatic function: adjust use in patients with impairment. - Drug interaction review: assess concomitant medications for cholinergic or anticholinergic effects. - Store at ambient temperature: keep in the original pack, protect from moisture.

Rivastigmine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Anticholinergic drugs: may reduce therapeutic efficacy. - Beta‑blockers: can increase risk of bradycardia. - Other cholinesterase inhibitors: additive cholinergic effects may be unsafe.

Moderate Interactions (Monitor Closely): - NSAIDs: heightened risk of gastrointestinal bleeding. - SSRIs and other antidepressants: may increase nausea. - Antihypertensives: potential enhancement of hypotensive effects.